We are committed and passionate about helping patients with serious, difficult-to-treat autoimmune and inflammatory disorders.
At Questcor our patients are our top priority. Through our research and development initiatives we strive to better understand serious, difficult-to-treat autoimmune and inflammatory disorders, as well as how our products can play a role in treating such conditions. By doing so we hope to help our patients live healthier, stronger, and more productive lives.
For more information on our marketed product please click the link below.
H.P. Acthar® Gel (repository corticotropin injection) is currently approved in the U.S. for the treatment of acute exacerbations of multiple sclerosis in adults, and as monotherapy for the treatment of infantile spasms in infants and children under 2 years of age. It is also indicated to induce a diuresis or a remission of proteinuria in nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus, for use during an exacerbation or as maintenance therapy in selected cases of systemic dermatomyositis (polymyositis), as well as indicated for the treatment of several other diseases and disorders.